Longeveron (NASDAQ: LGVN) announced that it has been selected from more than 600 worldwide applicants to advance to the final phase of the XPRISE Healthspan competition as a Milestone 2 Awardee team.
The $1,000,000 Milestone 2 Award is to be used towards the future competition clinical trial in accordance with the XPRIZE competition rules, with the opportunity to compete for the XPRIZE grand prize of up to $81 million.
XPRIZE Healthspan is a seven-year global competition incentivizing teams to develop and test therapeutics that restore muscle, cognition, and immune function in adults aged 50 to 90 by a minimum of 10 years, with an ambitious goal of 20 years, to extend healthy life within one year or less of treatment.
In a statement, Stephen H. Willard, CEO of Longeveron, commented, “We are extremely proud and enthusiastic to participate as a Milestone 2 Awardee of XPRIZE Healthspan, a seven-year, $101 million global competition that aims to revolutionize the way we approach human aging. We look forward to the next chapter of the competition as we continue to develop our stem cell therapy that we believe has the potential to have a significant impact for patients and their families, and extend healthy life.”
